Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 5/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749687 | 0.77 | CA12 (0.32) | CNR2 | |
| SCHEMBL6653750 | 0.76 | F2 (0.37) | PTGER1L3MBTL1CYP2C9MAPT | |
| SCHEMBL3249068 | 0.76 | SMN1; SMN2 (0.50) | L3MBTL1MAPTHTT | |
| SCHEMBL11959262 | 0.71 | BRD4 (0.51) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL6749182 | 0.71 | F2 (0.54) | — | |
| SCHEMBL6749389 | 0.70 | F2 (0.43) | — | |
| SCHEMBL13433963 | 0.68 | L3MBTL1 (0.52) | PTGER1PTGER4PTGER3PTGER2L3MBTL1 | |
| SCHEMBL18715976 | 0.68 | L3MBTL1 (0.52) | PTGER1PTGER4PTGER3PTGER2L3MBTL1 | |
| SCHEMBL3488737 | 0.68 | L3MBTL1 (0.52) | L3MBTL1HTTNPSR1 | |
| SCHEMBL7778567 | 0.68 | KDM4E (0.55) | L3MBTL1MAPTKDM4EMAPK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730783-B2 | REACTING AMINOGUANIDINE WITH CARBONYL COMPOUND TO FORM AMIDINOHYDRAZONE; REDUCTION; REACTING WITH ALKOXYAMINE; GUANIDINYLATION; ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6706765-B2 | ESPECIALLY TRYPSIN-LIKE SERINE PROTEASES, SUCH AS CHYMOTRYPSIN, TRYPSIN, THROMBIN, PLASMIN AND FACTOR XA. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-6638931-B1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | PTGER1 337/4885PTGER4 532/4885PTGER3 796/4885 |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | PLG, MMP9, F9 | PTGER1 225/4885PTGER4 424/4885PTGER3 607/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | PTGER1 306/4885PTGER4 479/4885PTGER3 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.